Table of Content

Introduction
Global Markets Direct Report Coverage
Beta Nerve Growth Factor (Beta NGF or NGF) - Overview
Beta Nerve Growth Factor (Beta NGF or NGF) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Beta Nerve Growth Factor (Beta NGF or NGF) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Beta Nerve Growth Factor (Beta NGF or NGF) - Companies Involved in Therapeutics Development
Akeso Inc
AstraZeneca Plc
Chengdu Easton Biopharmaceuticals Co Ltd
Dartsbio Pharmaceutical (Guangdong) Co Ltd
Fujimoto Pharmaceutical Corp
MimeTech Srl
Regeneron Pharmaceuticals Inc
Shandong Boan Biotechnology Co Ltd
Staidson BioPharma Inc
Zhuhai Trinomab Biotechnology Co Ltd
Beta Nerve Growth Factor (Beta NGF or NGF) - Drug Profiles
AK-115 - Drug Profile
Product Description
Mechanism Of Action
DS-002 - Drug Profile
Product Description
Mechanism Of Action
History of Events
EP-9001A - Drug Profile
Product Description
Mechanism Of Action
fasinumab - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy to Activate NGF for Diabetic Neuropathy and Peripheral Nerve Injury - Drug Profile
Product Description
Mechanism Of Action
MEDI-7352 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Monoclol Antibody to Target NGF beta in Chronic Back Pain, Cancer Pain and Osteoarthritis - Drug Profile
Product Description
Mechanism Of Action
MT-2 - Drug Profile
Product Description
Mechanism Of Action
History of Events
RBM-004 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Recombint Protein to Activate NGF Beta for Optic Nerve Injury - Drug Profile
Product Description
Mechanism Of Action
TNM-009 - Drug Profile
Product Description
Mechanism Of Action
TNM-010 - Drug Profile
Product Description
Mechanism Of Action
TNM-011 - Drug Profile
Product Description
Mechanism Of Action
udonitrectag - Drug Profile
Product Description
Mechanism Of Action
History of Events
Beta Nerve Growth Factor (Beta NGF or NGF) - Dormant Products
Beta Nerve Growth Factor (Beta NGF or NGF) - Discontinued Products
Beta Nerve Growth Factor (Beta NGF or NGF) - Product Development Milestones
Featured News & Press Releases
Feb 10, 2022: Approval of clinical trial of NGF monoclol antibody (AK115) for the treatment of pain (including cancer pain) firstly introduced by Akeso in the field of pain
Jan 01, 2021: Congratulations to DartsBio Pharmaceutical for algesic DS002 injection approved for clinical trial by NMPA
Dec 05, 2018: Recordati receives orphan drug desigtion for its investigatiol treatment for neurotrophic keratitis
Aug 17, 2018: Fasinumab Phase III osteoarthritis trial meets endpoints
Aug 17, 2017: Notice of the Start of a Japanese Phase 2/3 Clinical Study of the Anti-NGF Antibody MT-5547 in Osteoarthritis
Oct 17, 2016: Regeneron and Teva Provide Update on Fasinumab Clinical Development Programs
May 02, 2016: Regeneron Announces Positive Topline Results from Phase 2/3 Fasinumab Study in Patients with Osteoarthritis Pain
Dec 27, 2010: FDA Halts Development Of Regeneron’s Pain Drug
May 12, 2010: Regeneron Provides Initial Data On REGN475
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Akeso Inc, 2022
Pipeline by AstraZeneca Plc, 2022
Pipeline by Chengdu Easton Biopharmaceuticals Co Ltd, 2022
Pipeline by Dartsbio Pharmaceutical (Guangdong) Co Ltd, 2022
Pipeline by Fujimoto Pharmaceutical Corp, 2022
Pipeline by MimeTech Srl, 2022
Pipeline by Regeneron Pharmaceuticals Inc, 2022
Pipeline by Shandong Boan Biotechnology Co Ltd, 2022
Pipeline by Staidson BioPharma Inc, 2022
Pipeline by Zhuhai Trinomab Biotechnology Co Ltd, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Discontinued Products, 2022